Nasal spray may help MS sufferers
A new therapy for multiple sclerosis that would be sniffed rather than swallowed has shown promising results in laboratory tests. Jeremy Laurance, Health Editor, assesses hopes for a treatment that could be as simple to use as an asthma inhaler.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Scientists believe they may have found a way of protecting the body's tissues from attack when the immune system turns on itself, causing the nerve-cell damage that results in multiple sclerosis.
The disease, which affects about 85,000 people in the UK, causes wasting of the muscles and progressive paralysis as the myelin sheath surrounding nerve cells is destroyed. The body's immune system perceives the myelin as foreign, for reasons that are not understood, and attacks it as it would attack an invading infection.
Research by Professor David Wraith of the department of pathology and microbiology at the University of Bristol, using blood taken from MS sufferers, has shown that the auto-immune response that causes the damage can be switched off.
"We have found we can take the T-cells that are part of the body's immune system and re-educate them so they stop misbehaving," Professor Wraith said. "Potentially this is very important. Existing treatments are non- specific and tend to have side effects."
The research, to be presented at a symposium on "Regulating the Immune Response" at the United Medical and Dental Schools of Guy's and St Thomas's Hospitals in London tomorrow, is backed by the biotechnology company, Peptide Therapeutics, with funding from the Multiple Sclerosis Society, in a joint venture which guarantees the society a share of the royalties should the treatment prove effective. It is hoped that clinical trials will begin in 18 months.
Peter Cardy, chief executive of the MS society, said: "It is the first time we have entered into a collaboration of this kind, which has the potential to generate funds to be re-invested in supporting people with MS."
In multiple sclerosis, the T-cells in the immune system recognise specific regions of the protein sequence in the myelin against which they launch their attack. Professor Wraith and his team have shown that by challenging the T-cells with peptides that correspond to these regions the attack can be halted.
When given orally the results were disappointing, probably because the drug was broken down in the gut, but when administered as a nasal spray the suppression of immune response was highly promising.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments